Movement Alert｜Biogen Intraday Rise 5.05% in Regular Trading, BofA Raised Price Target Ahead of Earnings

Market Focus10-23

On October 23, Biogen rose 5.05% in Regular Trading, trading at $253.17 per share, with turnover of $349 million.

The move coincided with a fresh analyst action ahead of the company’s October 28 earnings release, with BofA raising its price target to $244 from $219. Broader sell-side sentiment also remained constructive, with FactSet-polled analysts showing an average overweight rating and a mean target near $246.69.

Near-term attention is centered on the upcoming quarterly report. Consensus estimates point to revenue of $2.634 billion, up 12.61% year over year, while adjusted EPS is expected at $1.99 to $2.04, down sharply from a year earlier, reflecting investor focus on revenue recovery, pipeline progress, and acquisition integration effects on profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment